The Company’s current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and is currently being prepared for licensing to a commercial partner within 12-18 months.
The Company originated from the Institute of Cancer Therapeutics – University of Bradford and, in addition to Sol, has acquired and developed a portfolio of specific cancer-targeting therapeutics through a pipeline agreement with the Institute of Cancer Therapeutics and other corporate acquisitions. Incanthera’s strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.
|Symbol||Ccy Code||Bid||Ask||Mid||Previous Close||Volume||Last Traded|
MiFID II compliant pre- and post-trade transaction data is available here. The data is delayed by at least 15 minutes and will be refreshed every 15 minutes. Publication of trades in equity securities that are large in scale compared to normal market size and illiquid non-equity securities may be delayed if the trade is eligible for deferred publication in accordance with the trading rules of Aquis Stock Exchange and MiFIR. Further details as to when the publication of a trade may be deferred are set out in the trading rules which are available here.
|Tradable securities in issue:||74,082,871|
|Sector:||Pharmaceuticals & Biotechnology|
|Date & Time||Volume||Price|
|08/04/21 | 14:54:22||20000||13|
|08/04/21 | 14:38:28||22727||13.2|
|08/04/21 | 13:11:38||7500||13.2|
|08/04/21 | 11:48:33||100000||12.8|
|07/04/21 | 16:19:15||781||12.8|
|07/04/21 | 14:16:57||3124||12.8|
|07/04/21 | 08:59:32||66667||12.5|
|06/04/21 | 08:45:02||41667||12.87|
|06/04/21 | 08:44:41||41667||12.8|
|01/04/21 | 10:57:57||64100||12.5|
|Date & Time||Title|
|01/04/21 | 07:00:00||Incanthera PLC - Company Webinar Presentation|
|23/03/21 | 07:00:00||Incanthera PLC - Placing to Raise £1,144,650|
|25/02/21 | 07:00:00||Incanthera PLC - Commercial Update|
|14/12/20 | 08:00:00||Incanthera PLC - Designation into new Apex market|
|08/12/20 | 07:00:00||Incanthera PLC - Half-year Report|
|04/12/20 | 16:08:00||Incanthera PLC - Notice of Interim Results|
|29/09/20 | 07:00:00||Incanthera PLC - Completion of Subscription Agreements|
|28/09/20 | 07:00:00||Incanthera PLC - Successful Results of Sensitisation Study|
|22/09/20 | 07:00:00||Incanthera PLC - Successful Results of Permeation Study|
|28/07/20 | 07:00:00||New Patent Filing for Sol Skin Cancer Technology|
Incanthera plc, 76 King Street, Manchester, M2 4NH, United Kingdom.
Phone: +44 (0) 161 817 5005
76 King Street, Manchester, M2 4NH, United Kingdom.
Cairn Financial Advisers LLP., Cheyne House, Crown Court, 62 - 63 Cheapside, London, United Kingdom.
Phone: +44 (0)20 7148 7900
Neville Registrars Limited , Neville House,Steelpark Road, Halesowen, West Midlands, B62 8HD, United Kingdom.
Phone: +44 (0) 121 585 1131